Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4499-4505

  Dernell, William S ^a   Withrow, Stephen J ^a   Straw, Rodney C ^a,c   Powers, Barbara E ^a   Drekke, John H ^b   Lafferty, Mary ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b THM Biomedical Inc   (United States)

^c West Chermiside Veterinary Clinic   (Australia)

Author keywords

Canine; Cisplatin; Intracavitary; Polymer; Sarcoma

Indexed keywords

CISPLATIN; POLYMER;

ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; INTRATUMORAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CISPLATIN; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; MITOTIC INDEX; NECROSIS; RECURRENCE; SARCOMA; TIME FACTORS;

EID: 0031418768     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. MacEwen EG, Withrow SJ: Soft Tissue Sarcomas. In: Withrow SJ, MacEwen EG., eds. Small Animal Clinical Oncology. Philadelphia: W.B. Saunders, 1996: 211-226.
2. Mills JHL, Nielsen SW: Canine hemangiopericytoma: A survey of 200 tumors. J Small Anim Pract 8: 599-604, 1967.
3. Postorino NC, Berg RJ, Powers BE, McChesney AE, Taylor RA, Withrow SJ: Prognostic variables for canine hemangiopericytoma: 50 cases (1979-1984). J Am Anim Hosp Assoc 24: 501-509, 1988.
4. Bostock DE, Dye MT: Prognosis after surgical excision of canine fibrous connective tissue sarcomas. Vet Pathol 17: 581-588, 1980.
5. McChesney-Gillette S, Dewhirst MW, Gillette EL, et al: Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: A randomized phase II study. Int J Hyperthermia 8: 309-320, 1992.
6. Graves GM, Bjorling DE, Mahaffey E: Canine hemangiopericytoma: 23 cases (1967-1984). J Am Vet Med Assoc 192: 99-102, 1988.
7. Kuntz CA, Dernell WS, Powers BE, Devitt CM, Straw RC, Withrow SJ: Treatment of soft tissue sarcomas of the trunk and extremities by surgery alone: 68 cases (Jan 1986-Jan 1996). Proc Vet Cancer Soc 109-110, 1996. (Abstract)
8. Mauldin GN, Meleo KA, Burk RL: Radiation therapy for the treatment of incompletely resected soft tissue sarcomas in dogs: 21 cases. Proc Vet Cancer Soc 111, 1993. (Abstract)
9. McChesney SL, Withrow SJ, Gillette EL, Powers BE, Dewhirst MW: Radiotherapy of soft tissue sarcomas in dogs. J Am Vet Med Assoc 194: 60-63, 1989.
10. Helphan SC: Chemotherapy for nonresectable and metastatic soft tissue tumors. Proc Kal Kan Symp 133-142, 1986. (Abstract)
11. Moore AS: Recent advances in chemotherapy for nonlymphoid malignant neoplasms. Comp Cont Ed Pract Vet 15: 1029-1045, 1993.
12. Ogilvie GK, Reynolds HA, Richardson RC, et al: Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 195: 1580-1583, 1989.
13. Casper ES, Gaynor JJ, Harrison LB, Panicek DM, Hajdu SI, Brennan MF: Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 73: 1644-1651, 1993.
14. Schmidt RA, Conrad EU, Collins C, Rabinovitch P, Finney A: Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 72: 2593-2601, 1993.
15. Straw RC, Withrow SJ, Douple EB et al: Effects of cis-diamminedichloroplatinum II released from D,L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res 12: 871-877, 1994.
16. Kodama K, Doi O, Tatsuta M, Kuriyama K, Tateishi R: Developement of postoperative intrathoracic chemo-thermotherapy for lung cancer with the objective of improving local cure. Cancer 64: 1422-1428, 1989.
17. ten Bokkel Huinink WW, Dubbelman R, Aartsen E, Franklin H, McVie JG: Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12: 43-46, 1985.
18. Moore AS, Kirk C, Cardona A: Intracavitary cisplatin chemotherapy experience in six dogs. J Vet Int Med 5: 227-231, 1991.
19. Withrow SJ, Straw RC: Local slow release cisplatin after limb sparing for canine osteosarcoma. Proc Eur Muskuloskel Oncol Soc 35, 1995. (Abstract)
20. Withrow SJ, Straw RC, Brekke JH. et al: Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Musculoskel Res 4: 105-110, 1995.
21. Ciekot PA, Powers BE, Withrow SJ, Straw RC: Pharmacokinetics and toxicity of cisdiamminedichloroplatinum II released from two types of polymer delivery systems implanted adjacent to the sciatic nerve in normal dogs. Proc Vet Cancer Soc 51-52, 1992. (Abstract)
22. Vauthey J, Woodruff JM. Brennan MF: Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): A 10-year experience. Ann Surg Oncol 2: 126-131, 1995.
23. Coindre J, Bui NB, Bonichon F, De Mascarel I, Trojani M: Histopathologic grading in spindle cell soft tissue sarcoma. Cancer 61: 2305-2309, 1988.
24. Evans SM: Canine Hemangiopericytoma: A retrospective analysis of response to surgery and orthovoltage radiation. Vet Radiol 28: 13-16, 1987.
25. Dorr RT, Alberts DS, Soble M: Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan and mitoxantrone. Cancer Chemother Pharmacol 16: 91-94, 1986.
26. Leyden M, Sullivan J: Full thickness skin necrosis due to inadvertent interstitial infusion of cisplatin. Cancer Treat Rep 67: 199, 1983.
27. Alekhteyar KM, Leung DH, Brennan MF, Harrison LB: The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys 36: 321-324, 1996.
28. Doussal VL, Coindre J, Leroux A, et al: Prognostic factors for patients with localized primary malignant fibrous histiocytoma: A multicenter study of 216 patients with multivariate analysis. Cancer 77: 1823-1830, 1996.
29. Cakir S, Oner Dincbas F, Uzel O, Koca SS, Okkan S: Multivariate analysis of prognostic factors in 75 patients with soft tissue sarcoma. Radiother Oncol 37: 10-16, 1995.
30. Zagars GK, Mullen JR, Pollack A: Malignant firous histiocytoma: Outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 34: 983-994, 1996.
31. Atwater SW, LaRue SM, Powers BE, Withrow SJ: Adjuvant radiotherapy of soft-tissue sarcomas in dogs. Proc Vet Cancer Soc 41-42, 1992. (Abstract)
32. Thrall DE, Prescott DM, Samulski TV, et al: Radiation plus local hyperthermia versus radiation plus the combination of local and whole-body hyperthermia in canine sarcomas. Int J Radiation Biol Phys 34: 1087-1096, 1996.
33. Theon AP, Pascoe JR, Meagher DM: Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae. J Am Vet Med Assoc 205: 1170-1176, 1994.
34. Begg AC, Deurloo MJM, Kop W, Bartelink H: Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors. Radiother Oncol 31: 129-137, 1994.
35. Theon AP, Madewell BR, Ryu J, Castro J: Concurrent irradiation and intratumoral chemotherapy with cisplatin: A pilot study in dogs with spontaneous tumors. Int J Radiat Oncol Biol Phys 29: 1027-1034, 1994.
36. Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 49: 3380-3384, 1989.
37. Los G, McVie JG: Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 26: 755-762, 1990.
38. Pagani O, Sessa C, Cavalli F: Platinum dose-intensity in solid tumors: Pharmacological and clinical perspectives. Bull Cancer 82 (Suppl 1): 16s-23s, 1995.
39. Troger V, Fischel JL, Formento P, Gioanni J, Milano G: Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur J Cancer 28: 82-86, 1992.
40. Rooser B, Attewell R, Berg NO, Rydholm A: Prognostication in soft tissue sarcoma: A model with four risk factors. Cancer 61: 817-823, 1988.